Synonyms: compound 16e [PMID: 30525599] | Jeselhy® | TAS-116 | TAS116
Compound class:
Synthetic organic
Comment: Pimitespib (TAS-116) is an orally bioavailable heat shock protein 90 α/β (HSP90α/β) inhibitor [6], that promotes proteasomal degradation of oncogenic HSP90 client proteins, and induces apoptosis of cells that overexpress (HSP90α/β). Reported to bind at the N-terminal ATP binding site of the target proteins [6]. Pimitespib was developed for potential antineoplastic activity [1,3-5].
|
|
No information available. |
Summary of Clinical Use ![]() |
Pimitespib was first approved for clinical use in Japan in July 2022 [2], as a treatment for gastrointestinal stromal tumour (GIST) that has progressed after chemotherapy. |